News Kailera's big obesity reveal puts pressure on shares Fresh from a record-breaking IPO, Kailera revealed keenly anticipated trial results for its oral weight-loss drug, to a mixed reaction.
News Obesity biotech Kailera's record-breaking IPO When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled.
News Alamar, Hemab, Kailera, and Seaport advance IPOs The last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings.
News Obesity-focused biotech Kailera joins IPO queue in US Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.
News Kailera, Hengrui stake claim to oral weight loss category Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.
News $600m round will help Kailera push obesity drug into phase 3 Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.